Therefore, identification of PARP1 and PHB2/PHB as hubs of the signaling pathways of MCC in human MM cells implicates potential use of PARP inhibitors and PHB ligands in the treatment of B cell malignancies involving aberrant expression of MCC. Here, PHB2 is linked to Miyoshi myopathy.